Enliven Therapeutics, Inc. (NASDAQ: ELVN) closed an upsized underwritten public offering on June 15, 2026, raising approximately $460.0 million in gross proceeds before deducting underwriting discounts, commissions, and other offering expenses.

The offering comprised 10,533,334 shares of common stock priced at $37.50 per share, including 1,600,000 additional shares from the full exercise of the underwriters' option. The company also issued pre-funded warrants to purchase 1,733,333 shares at $37.499 per warrant, representing the per-share public offering price less a $0.001 exercise price. All shares and pre-funded warrants were sold by Enliven.

Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley, and Barclays acted as joint book-running managers. Mizuho served as a book-running manager, LifeSci Capital as a passive book-running manager, Baird as lead manager, and Jones as manager.

The offering was made pursuant to a Registration Statement on Form S-3ASR that became automatically effective upon filing with the U.S. Securities and Exchange Commission on August 13, 2025. Enliven is a clinical-stage biopharmaceutical company based in Burlingame, California.